dynorphin A-(1-13) (Human) [3121]



dynorphin A-(1-13) (Human)


SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
InChIKey OVVIBUHLQIYUEU-IWIISZHXSA-N
Sequence YGGFLRRIRPKLK
HELM PEPTIDE1{Y.G.G.F.L.R.R.I.R.[dP].K.L.K}$$$$

Chemical Properties

Hydrogen bond acceptors 20
Hydrogen bond donors 22
Rotatable bonds 54
Log P -4.267
Molecular weight (Da) 1603.0
Stereochemistry info partial

Database connections

Model (AF2) κ δ μ
GPCRdb related ligands

Bioactivities

Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database
Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database

dynorphin A-(1-13) (Human)


Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Model (AF2) κ δ μ

Compound is not listed as a drug.